JP2006503913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503913A5 JP2006503913A5 JP2005501572A JP2005501572A JP2006503913A5 JP 2006503913 A5 JP2006503913 A5 JP 2006503913A5 JP 2005501572 A JP2005501572 A JP 2005501572A JP 2005501572 A JP2005501572 A JP 2005501572A JP 2006503913 A5 JP2006503913 A5 JP 2006503913A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- benzalkonium chloride
- composition according
- ophthalmic
- eye drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 26
- 229960000686 benzalkonium chloride Drugs 0.000 claims 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 8
- 239000003889 eye drop Substances 0.000 claims 6
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 206010030043 Ocular hypertension Diseases 0.000 claims 4
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 4
- 229960001160 latanoprost Drugs 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229960004605 timolol Drugs 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002997 ophthalmic solution Substances 0.000 claims 1
- 229940054534 ophthalmic solution Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42077602P | 2002-10-24 | 2002-10-24 | |
| US42104402P | 2002-10-25 | 2002-10-25 | |
| US10/429,677 US7074827B2 (en) | 2002-10-24 | 2003-05-06 | Method for treating ocular hypertension and glaucoma |
| PCT/JP2003/013452 WO2004037267A1 (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012125019A Division JP2012162570A (ja) | 2002-10-24 | 2012-05-31 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503913A JP2006503913A (ja) | 2006-02-02 |
| JP2006503913A5 true JP2006503913A5 (enExample) | 2006-12-07 |
Family
ID=32110845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501572A Pending JP2006503913A (ja) | 2002-10-24 | 2003-10-22 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
| JP2012125019A Pending JP2012162570A (ja) | 2002-10-24 | 2012-05-31 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012125019A Pending JP2012162570A (ja) | 2002-10-24 | 2012-05-31 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7074827B2 (enExample) |
| EP (2) | EP1553953B1 (enExample) |
| JP (2) | JP2006503913A (enExample) |
| AT (1) | ATE480240T1 (enExample) |
| AU (1) | AU2003274734A1 (enExample) |
| CA (1) | CA2502437C (enExample) |
| DE (1) | DE60334134D1 (enExample) |
| DK (1) | DK1553953T3 (enExample) |
| WO (1) | WO2004037267A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005039619A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan, Inc. | Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
| ATE412400T1 (de) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| DE102005035986B4 (de) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat |
| JP5247453B2 (ja) * | 2005-10-10 | 2013-07-24 | ノバガリ ファルマ エスア | プロスタグランジン含有眼科用カチオン性水中油型エマルジョン |
| US7666912B2 (en) * | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| TWI394564B (zh) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
| PL2066300T5 (pl) * | 2006-09-28 | 2020-03-31 | Novartis Ag | Samokonserwujące wodne kompozycje farmaceutyczne |
| FR2912207B1 (fr) * | 2007-02-01 | 2012-10-26 | Air Liquide | Procede et appareil de production de monoxyde de carbone par distillation cryogenique |
| EP2123278B1 (en) * | 2007-02-07 | 2013-01-09 | Teika Pharmaceutical Co., Ltd. | Eye drop preparation comprising latanoprost |
| JP2008247828A (ja) * | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | ラタノプロストを含有する水性医薬組成物。 |
| FR2918891B1 (fr) * | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| JP2009040727A (ja) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | ラタノプロストを有効成分とする安定な点眼液剤 |
| ES2511840T3 (es) * | 2007-08-29 | 2014-10-23 | Wakamoto Pharmaceutical Co., Ltd. | Composición farmacéutica acuosa que contiene latanoprost |
| MX2007011165A (es) * | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Composición farmacéutica estable de timolol, dorzolamida y brimonidina. |
| PL2254549T5 (pl) * | 2008-03-17 | 2019-12-31 | Alcon Research, Ltd. | Wodne kompozycje farmaceutyczne zawierające kompleksy boran-poliole |
| TWI544927B (zh) * | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
| EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| JP2010275259A (ja) * | 2009-05-29 | 2010-12-09 | Toa Yakuhin Kk | 均一、かつ安定なラタノプロスト点眼液剤組成物 |
| TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸－多元醇錯合物之水性藥學組成物 |
| EP2269575A1 (en) | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Method for improving bioavailability of latanoprost |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| FR2961694B1 (fr) | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| WO2012015998A2 (en) | 2010-07-29 | 2012-02-02 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| EP2598117A2 (en) * | 2010-07-29 | 2013-06-05 | Allergan, Inc. | Preservative free bimatoprost solutions |
| EP2452669A1 (en) | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| CA2866067C (en) | 2011-01-19 | 2015-04-21 | Topokine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| AU2013245946A1 (en) * | 2012-04-10 | 2014-11-27 | Eyenovia, Inc. | Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration |
| US20130299607A1 (en) | 2012-04-20 | 2013-11-14 | Corinthiam Ophthalmic, Inc. | Spray ejector device and methods of use |
| KR102168906B1 (ko) | 2012-05-14 | 2020-10-22 | 아이노비아 인코포레이티드 | 층류 액적 생성기 디바이스 및 이용 방법들 |
| SG11201407431RA (en) | 2012-05-15 | 2014-12-30 | Eyenovia Inc | Ejector devices, methods, drivers, and circuits therefor |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| WO2014081941A1 (en) | 2012-11-21 | 2014-05-30 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| NO2753788T3 (enExample) | 2013-05-10 | 2018-06-16 | ||
| US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| WO2015029923A1 (ja) * | 2013-08-26 | 2015-03-05 | ロート製薬株式会社 | 眼科用製剤 |
| GR1008483B (el) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| WO2016021371A1 (ja) | 2014-08-05 | 2016-02-11 | ソニー株式会社 | 直流電力送電装置、直流電力受電装置及び直流電力送電システム |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| GR1009040B (el) | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| WO2018054932A1 (en) | 2016-09-22 | 2018-03-29 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| CN109906085B (zh) | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| MY206642A (en) | 2018-10-12 | 2024-12-30 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| MD3886799T2 (ro) | 2019-08-07 | 2024-01-31 | Aneira Pharma Inc | Compoziții pentru tratamentul căderii părului |
| AU2020340561A1 (en) | 2019-09-06 | 2022-03-31 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| JP2022120120A (ja) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420857T1 (de) * | 1988-09-06 | 2009-01-15 | Pfizer Health Ab | Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| AU7680096A (en) | 1995-12-22 | 1997-07-17 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| JPH10259179A (ja) * | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | 多置換アリールオキシ基を有するプロスタグランジン類およびその用途 |
| AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| US6646001B2 (en) * | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| JP4000505B2 (ja) | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
| SE0002211D0 (sv) | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| AU2001286210A1 (en) | 2000-09-13 | 2002-03-26 | Asahi Glass Company, Limited | Eye drops |
| JP3876355B2 (ja) * | 2000-09-13 | 2007-01-31 | 参天製薬株式会社 | 点眼液 |
| US20030018079A1 (en) | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
| US7249174B2 (en) * | 2002-06-12 | 2007-07-24 | Bladelogic, Inc. | Method and system for executing and undoing distributed server change operations |
| US20050228048A1 (en) * | 2002-08-23 | 2005-10-13 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
| CA2498233C (en) | 2002-09-09 | 2012-08-14 | Santen Pharmaceutical Co., Ltd. | Clear ophthalmic solution comprising latanoprost as active ingredient |
-
2003
- 2003-05-06 US US10/429,677 patent/US7074827B2/en not_active Expired - Fee Related
- 2003-10-22 DE DE60334134T patent/DE60334134D1/de not_active Expired - Lifetime
- 2003-10-22 AT AT03758746T patent/ATE480240T1/de active
- 2003-10-22 AU AU2003274734A patent/AU2003274734A1/en not_active Abandoned
- 2003-10-22 CA CA2502437A patent/CA2502437C/en not_active Expired - Fee Related
- 2003-10-22 EP EP03758746A patent/EP1553953B1/en not_active Expired - Lifetime
- 2003-10-22 EP EP10171708A patent/EP2253322A1/en not_active Withdrawn
- 2003-10-22 DK DK03758746.6T patent/DK1553953T3/da active
- 2003-10-22 WO PCT/JP2003/013452 patent/WO2004037267A1/en not_active Ceased
- 2003-10-22 JP JP2005501572A patent/JP2006503913A/ja active Pending
-
2006
- 2006-05-23 US US11/438,290 patent/US8673973B2/en not_active Expired - Fee Related
-
2012
- 2012-05-31 JP JP2012125019A patent/JP2012162570A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503913A5 (enExample) | ||
| CA2502437A1 (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
| CN102811610B (zh) | 无刺激性眼科聚维酮碘组合物 | |
| TWI298257B (en) | Hypotensive lipid and timolol compositions and methods of using same | |
| US8785393B2 (en) | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists | |
| JP6014033B2 (ja) | 防腐剤無添加ビマトプロストおよびチモロール溶液 | |
| US20080233053A1 (en) | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients | |
| JP2005523316A5 (enExample) | ||
| Kroll et al. | Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma | |
| US20120027842A1 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| JP2014515383A5 (enExample) | ||
| JP4933897B2 (ja) | 眼内移行性促進水性点眼剤 | |
| ES2210018T3 (es) | Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma. | |
| AU2011282679A1 (en) | Preservative free bimatoprost solutions | |
| JP5132015B2 (ja) | 点眼剤組成物 | |
| JP5725786B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| Day et al. | Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension | |
| JP2011518828A (ja) | 眼球障害の処置のためのｐａｉ−１の発現および活性インヒビター | |
| CN107412211A (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| KR20150119082A (ko) | 국소 안구 진통제 | |
| ES2452026T3 (es) | Prostaglandinas y análogos como agentes para disminuir la presión intraocular | |
| JP5041761B2 (ja) | 眼粘膜適用製剤 | |
| JP4470393B2 (ja) | 安定である点眼剤 | |
| JPH08231400A (ja) | イフェンプロジルを必須成分とする眼圧降下剤 | |
| Schacknow et al. | Medications used to treat glaucoma |